How to Write a Business Plan in 7 Steps: Medical Device Manufacturing
How to Write a Business Plan for Medical Device Manufacturing
This guide helps founders structure their plan, focusing on critical areas like FDA compliance, high fixed costs (starting at $43,800 monthly), and scaling EBITDA from $312 million (Year 1) to $2537 million (Year 5)
How to Write a Business Plan for Medical Device Manufacturing in 7 Steps
#
Step Name
Plan Section
Key Focus
Main Output/Deliverable
1
Define Product & Regulatory Strategy
Concept
Detail five devices, FDA classification, and QMS needs
Regulatory pathway defined
2
Target Market & Sales Model
Market
Identify hospital systems; project sales growth (100 units 2026 to 550 units 2030)
Sales forecast structure
3
Establish Manufacturing & COGS
Operations
Outline production; $200,000 Cleanroom CapEx; calculate unit costs
What specific regulatory pathway must our devices follow for FDA approval?
The regulatory pathway for the Medical Device Manufacturing business hinges entirely on classifying their surgical tools and diagnostic equipment as Class I, II, or III devices, which dictates the required FDA submission—likely a 510(k) for many surgical tools—and subsequent timeline risks; understanding this upfront is crucial for accurate capital planning, as detailed in What Is The Primary Metric That Reflects The Success Of Your Medical Device Manufacturing Business?
Device Classification Impact
Class I devices often require only registration and listing; these are low-risk tools.
Class II devices typically need a 510(k) premarket notification, taking roughly 90 days review time post-submission.
Class III devices, high-risk novel tech, require a PMA (Premarket Approval), which can take 1–3 years.
If your diagnostic equipment is novel, defintely budget for the longer PMA timeline to avoid cash flow surprises.
Ongoing Compliance Costs
Post-market surveillance requires mandatory Medical Device Reporting (MDR) for adverse events.
Annual FDA establishment registration costs $5,400 for the current cycle.
Quality System Regulation (QSR) compliance demands ongoing audits and documentation upkeep.
Expect 10% to 15% of initial R&D costs to recur annually for compliance maintenance.
How will we fund the $1115 million in initial capital expenditures (CapEx)?
Funding the $1.115 billion initial Capital Expenditures (CapEx) for Medical Device Manufacturing requires balancing debt capacity against equity dilution while maintaining a $1.097 billion cash reserve; this structure must support the modeled 0.49% Internal Rate of Return (IRR), a return profile that demands careful comparison against industry benchmarks, which you can read more about here: How Much Does The Owner Of Medical Device Manufacturing Business Typically Make?. We need to secure roughly $2.212 billion total before breaking ground.
Funding Mix Strategy
Determine the optimal debt-to-equity ratio for the $2.212 billion requirement.
Use equity for initial site acquisition and tooling costs.
Secure long-term debt based on projected asset collateral value.
Analyze covenants tied to debt servicing capacity.
Buffer and Return Targets
The $1.097 billion cash buffer must cover initial operating losses.
Model the cash burn rate to ensure the buffer lasts until positive cash flow is achieved, defintely.
A 0.49% IRR suggests heavy reliance on terminal value or very long payback periods.
Stress test revenue ramp assumptions supporting the 0.49% hurdle rate.
What is the true fully-loaded Cost of Goods Sold (COGS) for each device?
The true fully-loaded Cost of Goods Sold (COGS) for each device requires separating direct variable unit costs from revenue-based overhead to establish defensible gross margin targets.
Pinpoint Variable Unit Costs
Isolate direct material costs, like the $50 material cost for a surgical stapler component.
Add direct labor and any unit-specific overhead tied to the production line.
This sum forms your baseline cost floor before allocating any fees tied to sales volume.
If you don't track this precisely, margin erosion is defintely possible.
Set Gross Margin Targets
Layer revenue-based overhead, such as the 15% regulatory and QA fees, on top of variable COGS.
These fees scale with revenue, unlike fixed factory rent, so they must be baked into the selling price.
Your target gross margin must absorb these costs and still cover operating expenses.
Do we have the specialized talent needed for R&D and Quality Control (QC)?
The $897,500 Year 1 salary budget is justified by immediately securing the Regulatory Affairs Manager, which is essential groundwork before scaling engineering staff from 10 FTE to 30 FTE by 2030. This upfront investment in compliance de-risks future product launches for the Medical Device Manufacturing operation.
Securing Year 1 Compliance Talent
The Regulatory Affairs Manager salary of $130,000 is a critical part of the $897,500 total Year 1 compensation outlay.
This role is needed now to manage FDA submissions for the focused portfolio of devices.
We defintely need this expertise before adding significant R&D headcount.
If onboarding takes 14+ days, churn risk rises among early hires.
Engineering Scale and Quality Control Pipeline
The plan requires scaling engineering from 10 FTE today up to 30 FTE by 2030.
Each new engineer demands robust Quality Control (QC) oversight during product design.
This initial staffing supports the multi-year product launch schedule.
Successfully justifying the $1,115 million initial Capital Expenditure (CapEx) and securing a minimum cash buffer of $1,097 million are mandatory prerequisites for funding the startup phase.
The financial model must demonstrate aggressive scalability by projecting EBITDA growth from $312 million in Year 1 to $2,537 million by Year 5, justifying an ambitious 7,116% Return on Equity (ROE).
Regulatory strategy dictates operational structure, demanding immediate investment in specialized talent, such as a $130,000 Regulatory Affairs Manager, and defining the specific FDA pathway for all five core devices.
Accurate Cost of Goods Sold (COGS) modeling requires separating variable unit costs, like $50 for materials, from revenue-based overhead fees to ensure high gross margin targets are met.
Step 1
: Define Product & Regulatory Strategy
Regulatory Path Lock
Defining these five devices locks in your regulatory path and dictates the compliance timeline. Each product needs a defined intended use to determine its FDA classification—Class I, II, or III. This classification directly drives your Quality Management System (QMS) compliance burden. Getting this wrong delays market entry, jeopardizing the aggressive Month 1 breakeven target.
The QMS, often based on 21 CFR Part 820, must be ready before the Cleanroom Setup ($200,000 CapEx) is fully validated for production. If onboarding regulatory expertise takes too long, the $180,000 Head of R&D salary becomes pure burn before revenue starts flowing from your planned unit sales.
Actionable Classification
Map the five devices immediately to their likely FDA class based on risk. Surgical tools are often Class II, requiring 510(k) clearance, while simple diagnostic aids might be Class I. This classification determines whether you need a full QMS audit or just basic design controls documentation right now.
Implement a lean QMS from day one, focusing documentation efforts on the highest-risk items—likely the diagnostic equipment. Documenting processes now saves expensive rework later, which is critical when managing $43,800 monthly fixed OpEx. Don't wait for the first unit sale to finalize your control procedures; they are part of the product.
1
Step 2
: Target Market & Sales Model
Customer Channel Lock
You need to know exactly who writes the check—hospital systems and large distributors are your primary customers, not individual clinics. This choice dictates your sales cycle length and required regulatory support. If you plan to ship just 100 Portable Ultrasounds in 2026, that initial volume is highly dependent on signing just a few major accounts. This channel choice is defintely the make-or-break factor for early revenue stability.
The immediate financial pressure comes from the sales terms. You must model aggressively against the stated 50% commission structure for 2026. This high take rate means your unit economics must support a massive upfront cost just to get the device placed. You’re betting that volume growth, hitting 550 units by 2030, will eventually dilute the impact of that initial high commission rate.
Sales Growth Levers
Your action item is locking down those anchor contracts now. Selling direct requires significant internal sales headcount, but it gives you control over pricing and data. If you rely on distributors, ensure your contract defines clear volume tiers that automatically reduce the 50% commission percentage as you cross certain shipment thresholds.
To support the projection of moving from 100 units in 2026 to 550 units in 2030, you must have a clear plan for expanding your sales territory or product line coverage. What drives the next 450 units? If the price per unit is $1,000, that first year’s commission eats up $500 per unit before you even look at manufacturing costs. That margin pressure is real.
2
Step 3
: Establish Manufacturing & COGS
Manufacturing Foundation
Establishing production sets your gross margin, which is the bedrock of valuation. The initial $200,000 Cleanroom Setup capital expenditure (CapEx) is non-negotiable for quality compliance in medical devices. Defintely get this right, because errors here cascade into regulatory risk and higher rework costs later.
This step ties directly to your US-based manufacturing promise. You need clear line-of-sight on assembly time and material overhead for all five devices before setting final pricing. Don't underestimate the overhead required just to maintain the controlled environment.
Unit Cost Calculation
To determine true Cost of Goods Sold (COGS), you must detail direct costs for every unit. This granular view separates profitable products from those that only look good on paper. Focus on minimizing variability in your material sourcing agreements now.
For each of the five products, your unit cost calculation must sum these core elements:
Direct Material Costs (Bill of Materials)
Direct Assembly Labor Hours
Allocated Cleanroom Overhead Rate
Packaging and Inspection Costs
3
Step 4
: Model Capital Expenditures
CapEx Foundation
Modeling capital expenditures defines your operational ceiling before you sell a single device. This isn't just budgeting; it sets the physical limits for your Step 3 manufacturing plan. If the Advanced CNC Machining Center at $350,000 is delayed, your ability to produce high-precision surgical tools stops dead. You must sequence these large purchases against your funding drawdown schedule.
The total $1,115,000 investment must be fully itemized across machinery, tooling, and cleanroom buildout, including the $200,000 Cleanroom Setup. Failure to account for these upfront costs means you will run out of cash before achieving scale. Honestly, this is where most hardware startups fail to plan properly.
OpEx Linkage
You must lock down the $43,800 monthly fixed operating expenses (OpEx) figure now. This number is your minimum monthly burn rate covering salaries, rent, and utilities before any revenue comes in. Crucially, check if this OpEx already includes the depreciation expense tied to the new $1,115,000 in assets you just modeled. If it doesn't, your break-even point calculation in Step 6 will be wrong.
Defintely map every major purchase to a specific production milestone. This spending dictates your timeline for hitting the 2026 sales target of 100 Portable Ultrasounds. Here’s the quick math: if depreciation is excluded from the $43.8k, you need to add it back to find the true cash burn. This requires careful coordination with your accounting team.
Verify asset useful lives for depreciation schedules.
Confirm $43.8k covers all non-production overhead.
Tie large CapEx payments to specific funding tranches.
4
Step 5
: Build the Organizational Chart
Headcount Justification
Building the team of 65 Full-Time Equivalents (FTEs) defines your initial operational capacity. This structure must support the five planned devices and the necessary Quality Management System (QMS) requirements. The $180,000 salary for the Head of R&D anchors your innovation pipeline, which is key to meeting the multi-year product launch schedule. Getting this initial mix right prevents immediate operational bottlenecks in design and compliance.
Scaling Headcount
Tie future hiring directly to production volume milestones. For instance, scaling from 100 Portable Ultrasounds shipped in 2026 to 550 by 2030 requires proportional scaling in manufacturing labor and quality assurance staff. Ensure the current $43,800 monthly fixed operating expenses (OpEx) can absorb the initial 65 salaries before triggering significant revenue. This headcount plan needs constant review against unit cost targets.
5
Step 6
: Create 5-Year Financial Projections
Confirming Breakeven Velocity
Building the 5-year projection hinges on validating that aggressive Month 1 breakeven goal. You must tie projected unit volume growth directly to pricing assumptions. For instance, if the Surgical Stapler starts at $500 and hits $520 by 2030, that price escalator must cover rising COGS and fixed overhead. If unit sales lag early on, that Month 1 target collapses fast. This model tests if your sales velocity assumptions are realistic enough to support your burn rate.
Validate Month 1 Burn
To confirm that aggressive Month 1 breakeven, calculate required gross profit against the $43,800 monthly fixed operating expenses (OpEx). If 2026 sales carry a 50% commission structure, your net margin on sales is immediately tight. You need enough volume to cover that $43.8k OpEx plus the variable costs. If sales start slow, say only 100 Portable Ultrasounds shipped that first month, the revenue won't cover the burn, defintely pushing breakeven past Month 1.
6
Step 7
: Determine Funding Needs & Risks
Cash Threshold
You need capital to bridge the gap until sales cover fixed costs. The absolute minimum cash requirement identified is $1,097,000. This number covers initial operating expenses, like the $43,800 monthly overhead, plus initial inventory and regulatory hurdles. If you raise less, you risk running out of runway before hitting critical milestones. Securing this floor amount is non-negotiable for operational continuity.
Upside Justification
Investors look past the burn rate to the potential payoff. This model projects an aggressive 7116% Return on Equity (ROE), signaling massive shareholder value creation if execution holds. Furthermore, Year 5 EBITDA hits an eye-watering $2,537 million. What this estimate hides is the dependency on hitting the aggressive sales targets outlined in Step 6. We must defintely model sensitivities around these projections.
